INCR Intercure Ltd.

$4.10 -10.28%

Data as of Nov 2, 2026 close

Healthcare · Pharmaceutical Preparations

Intercure Ltd. (INCR) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $45 million. Shares last traded at $4.10, 43.8% below their 52-week high.

Market Cap

$45M

Shares Out

10.9M

EPS (TTM)

—

P/E (TTM)*

—

P/S Ratio

—

P/B Ratio

—

Dividend / Share

—

Dividend Yield

—

52-Week High

$7.30

52-Week Low

$3.45

Volume (venue)

3,918

Avg Vol (3m, venue)

387.295

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Intercure Ltd. reports in ILS: EPS, dividends and financials are shown in ILS as filed. The Federal Reserve H.10 release publishes no ILS rate, so there is no USD-priced ratio.

Performance

—

YTD

+13.89%

—

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. INCR split history →

Technicals

RSI (14)

35.60

SMA (50)

$4.99

SMA (200)

$5.90

Price vs SMA50

-17.87%

Price vs SMA200

-30.52%

ATR (14)

$0.32

Full technical analysis (26 indicators, D/W/M) →

Pharmaceutical Preparations peers

INCR vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of Nov 2, 2026 close

1–14 of 14


LLY	Lilly (Eli)	$1.33T	48.13	15.35	31.9%	-0.28%
JNJ	Johnson & Johnson	$652.2B	40.52	6.57	16.2%	-0.82%
ONC	Beone Medicines Ltd.	$533.8B	814.05	87.09	10.7%	-2.48%
ABBV	AbbVie	$510.3B	80.87	7.93	9.8%	-2.05%
MRK	Merck	$366.4B	115.46	5.50	4.8%	-0.22%
ABT	Abbott Laboratories	$192.1B	30.61	4.26	13.9%	+3.81%
PFE	Pfizer	$175.0B	40.41	2.75	6.8%	+0.69%
VRTX	Vertex Pharmaceuticals	$144.5B	32.80	11.48	35.0%	+1.96%
BMY	Bristol Myers Squibb	$128.8B	13.94	2.58	18.5%	+0.90%
REGN	Regeneron Pharmaceuticals	$99.4B	20.64	5.89	28.5%	+3.63%
TEVA	Teva Pharmaceutical Industries Ltd	$47.4B	67.14	2.74	4.1%	-3.35%
ZTS	Zoetis	$34.4B	13.14	3.61	27.5%	+4.35%
RPRX	Royalty Pharma Plc	$29.6B	36.35	11.68	32.1%	-0.98%
ROIV	Roivant Sciences Ltd.	$25.9B	—	3441.87	—	-2.76%

Source: SEC EDGAR (fundamentals/EPS/dividends, reported in ILS) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.